The strong EPS beat, cash runway into 2029, and multiple pipeline catalysts (ABI-6250 Phase 2 in HDV and cholestatic diseases, GS-1179 Phase 2 in HSV) provide a clear catalyst path. Monitor the opt-in decision on the Gilead HSV program by year-end 2026 and Phase 2 data readouts for ABI-6250.
Price Chart
Executive Summary
Assembly Biosciences reported Q2 2026 EPS of -$0.20, beating consensus of -$0.53 by 62.3%, and collaboration revenue of $13.4M vs $9.6M a year ago. The company completed a $115M gross financing, expanded ABI-6250 into cholestatic liver diseases, and has cash runway into 2029 including a $75M Gilead payment. The strong EPS beat and pipeline progress are positive, but the company remains pre-revenue from product sales and the beat is partly due to a $5.1M catch-up adjustment.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.20 vs consensus -$0.53 (beat by 62.3%)
- Q2 2026 collaboration revenue $13.4M vs $9.6M YoY, including $5.1M cumulative catch-up adjustment
- Cash, cash equivalents and marketable securities $320.4M as of June 30, 2026, up from $226.6M at March 31, 2026
- Completed $115M gross financing to support pipeline advancement
- ABI-6250 expanded into cholestatic liver diseases (PBC, PSC) with Phase 2 expected Q1 2027
- GS-1179 selected to advance in HSV HPI program, Phase 2 initiation expected by year-end 2026
- Cash runway projected into 2029, including $75M Gilead extension payment due Q4 2026
- Net loss narrowed to $3.9M from $10.2M YoY
Financial Impact
EPS beat consensus by $0.33 (62.3%), revenue $13.4M vs $9.6M YoY; cash position strengthened by $93.8M QoQ
Risk Factors
- Pre-revenue biotech with no approved products; all candidates are investigational
- EPS beat partially driven by $5.1M one-time catch-up adjustment, not recurring
- Dependence on Gilead collaboration for revenue and pipeline advancement
- Clinical trial risks: Phase 2 studies may fail to meet endpoints
- Dilution risk: weighted average shares outstanding increased to 18.9M from 7.7M YoY
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344875 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 10w ago | Institutional Cluster | $30.01 $35.28 | ▲ +17.56% | ▲ +18.75% | $20.30 (−32.36%) |
Aug 13, 2026 10w ago | Press Release | $32.95 $34.38 | ▲ +4.34% | ▲ +5.71% | $20.30 (−38.39%) |
Jun 11, 2026 19w ago | Institutional Cluster | $22.53 $24.15 | ▲ +7.19% | ▲ +6.76% | $20.30 (−9.90%) |
Jun 5, 2026 20w ago | 8-K | $22.56 $23.34 | ▲ +3.48% | ▲ +1.37% | $20.30 (−10.00%) |
May 22, 2026 22w ago | 424B5 | $28.75 $26.92 | ▲ +6.37% | ▲ +7.45% | $20.30 (+29.39%) |
May 22, 2026 22w ago | 8-K | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.30 (−28.37%) |
May 22, 2026 22w ago | Press Release | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.30 (−28.37%) |
May 7, 2026 24w ago | Press Release | $29.74 $30.30 | ▲ +1.88% | ▲ +0.42% | $20.30 (−31.74%) |
Mar 30, 2026 30w ago | EFFECT | $26.64 $28.53 | ▲ +7.09% | ▲ +2.79% | $20.30 (−23.80%) |
Mar 19, 2026 31w ago | Press Release | $28.46 $27.70 | ▼ −2.67% | ▼ −0.52% | $20.30 (−28.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers